European Small Caps With Insider Action: Undervalued Picks For May 2025

In This Article:

As European markets navigate a landscape marked by easing trade tensions and mixed economic signals, the pan-European STOXX Europe 600 Index has shown resilience, rising for a fourth consecutive week. In this environment, small-cap stocks in Europe present intriguing opportunities for investors, particularly those with insider activity that may signal confidence in their potential. Identifying stocks with strong fundamentals and strategic positioning can be key to capitalizing on these market dynamics.

Top 10 Undervalued Small Caps With Insider Buying In Europe

Name

PE

PS

Discount to Fair Value

Value Rating

Morgan Advanced Materials

11.4x

0.5x

38.20%

★★★★★☆

Savills

24.6x

0.5x

41.18%

★★★★☆☆

FRP Advisory Group

12.4x

2.2x

14.87%

★★★★☆☆

AKVA group

15.2x

0.7x

49.12%

★★★★☆☆

Close Brothers Group

NA

0.5x

49.44%

★★★★☆☆

Eastnine

17.8x

8.6x

40.61%

★★★★☆☆

Tristel

30.7x

4.3x

17.98%

★★★☆☆☆

Italmobiliare

11.2x

1.5x

-276.14%

★★★☆☆☆

Arendals Fossekompani

NA

1.6x

41.75%

★★★☆☆☆

Seeing Machines

NA

2.2x

49.69%

★★★☆☆☆

Click here to see the full list of 60 stocks from our Undervalued European Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

Tristel

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Tristel is a company specializing in infection prevention and contamination control products, primarily serving the healthcare sector with a market cap of £0.25 billion.

Operations: The primary revenue streams are Hospital Medical Device Decontamination (£37.68 million) and Hospital Environmental Surface Disinfection (£3.51 million). The gross profit margin has shown an upward trend over the years, reaching 81.42% by December 2024. Operating expenses have increased alongside revenue growth, with general and administrative expenses being a significant component of the cost structure.

PE: 30.7x

Tristel, a small European company, is navigating the healthcare sector with its innovative disinfectant products. Recent insider confidence was shown through share purchases in March 2025. The company's submission of additional data for FDA approval of Tristel OPH could significantly impact U.S. ophthalmic practices by June 2025. Financially, Tristel reported sales growth to £22.57 million for the half-year ending December 2024, despite a slight dip in net income to £2.73 million from the previous year. With earnings forecasted to grow annually by 19%, and an increased interim dividend to 5.68 pence paid in April 2025, Tristel presents potential growth opportunities amidst its funding challenges relying solely on external borrowing.